Kiniksa Pharmaceuticals International Plc (KNSA) - News Archive

Kiniksa Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for KPL-387 in Pericarditis Treatment LONDON, Oct. 17, 2025 Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA), a biopharmaceutical company focuse...

In recent news, shares of Kiniksa Pharmaceuticals Ltd (KNSA) have experienced a significant increase, causing investors to question the optimal time to sell. This article aims to delve into the underlying reasons for th...

Sjögren s Disease is a chronic autoimmune disorder characterized by dryness of the eyes and mouth due to the immune system attacking the moisture-producing glands. It affects millions of people worldwide, predominantly...

In the ever-evolving biopharmaceutical industry, Kiniksa Pharmaceuticals continues to strengthen its position with recent development updates for its novel compound, Abiprubart. Among these impactful advancements, the c...

Kiniksa Pharmaceuticals has announced yet another remarkable milestone in its Q4 financial report. A key highlight of this announcement is the firm s impressive growth surge for its product ARCALYST (rilonacept), which...